Pharmaceuticals Australia

Australia Compounded Weight Loss Medications Market Analysis, 2024–2034

Australia Compounded Weight Loss Medications Market Industry Trends and Forecast to 2034: Segmented by (Drug, Channel, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $19.1 Mn Estimated value
Estimate 2025 $21.6 Mn 1.2% of the global market
Projected 2034 $67.0 Mn 210.1% Adds $45.4 Mn over 9 forecast years
CAGR 2025–2034 13.4% Faster than 67% of 180 Pharmaceuticals markets here
Key players 5 Companies profiled
  • Australia is 1.23% of the global market.
  • In APAC, the largest is China at $151.5 Mn.
  • Fastest growing: India at 15.3% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$45.4 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Compounded Weight Loss Medications Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $19.1 Mn — —
2025 (base) $21.6 Mn +$2.6 Mn —
2026 (forecast) $24.5 Mn +$2.9 Mn +13.4%
2027 (forecast) $27.8 Mn +$3.3 Mn +28.6%
2028 (forecast) $31.5 Mn +$3.7 Mn +45.8%
2029 (forecast) $35.7 Mn +$4.2 Mn +65.4%
2030 (forecast) $40.5 Mn +$4.8 Mn +87.5%
2031 (forecast) $45.9 Mn +$5.4 Mn +112.7%
2032 (forecast) $52.1 Mn +$6.2 Mn +141.2%
2033 (forecast) $59.1 Mn +$7.0 Mn +173.5%
2034 (forecast) $67.0 Mn +$7.9 Mn +210.1%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $1.76 Bn
  2. North America $927.2 Mn
  3. US $819.7 Mn
  4. Europe $373.8 Mn
  5. APAC $367.0 Mn
  6. China $151.5 Mn
  7. Canada $144.4 Mn
  8. Japan $119.6 Mn
  9. Latin America $77.3 Mn
  10. Germany $68.9 Mn
  11. Middle East $61.0 Mn
  12. UK $49.9 Mn
  13. France $46.2 Mn
  14. Brazil $41.6 Mn
  15. Italy $38.5 Mn
  16. Spain $34.9 Mn
  17. Saudi Arabia $35.2 Mn
  18. Ecuador $34.0 Mn
  19. Africa $29.6 Mn
  20. India $29.1 Mn
  21. Mexico $22.7 Mn
  22. Australia (this report) $21.6 Mn
  23. Russia $19.0 Mn
  24. New Zealand $15.4 Mn
  25. South Africa $12.8 Mn
  26. UAE $9.9 Mn
  27. Egypt $5.7 Mn
  28. Philippines $3.7 Mn
  29. Hong Kong $2.7 Mn
  30. Malaysia $2.5 Mn
  31. Singapore $2.3 Mn
  32. Thailand $1.9 Mn
  33. Kenya $1.2 Mn

The Australia Compounded Weight Loss Medications Market Analysis Executive Summary

Compounded weight loss medications are pharmacy-prepared versions of weight-loss drugs, made for individual patients, often during shortages of branded products.

Key segments of the compounded Weight Loss Medications market include drug (Compounded Semaglutide, Compounded Tirzepatide and Others) and channel (Compounding Pharmacies, Telehealth Platforms and Clinics).

Australia Compounded Weight Loss Medications Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the compounded Weight Loss Medications market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the compounded Weight Loss Medications market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the compounded Weight Loss Medications market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Compounded Weight Loss Medications Market in Australia

The compounded Weight Loss Medications market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Compounded Weight Loss Medications Market in Australia

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for compounded Weight Loss Medications. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Compounded Weight Loss Medications right now, from free public sources.

Latest research 9 papers since 2021 (worldwide)

  1. Compounded GLP-1 Dispensing Patterns and Vitamin B12 Coformulation. JAMA, 2026
  2. Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand. JAMA health forum, 2026
  3. Angioedema After Accidental Semaglutide Dosing Error: A Case Report. Journal of clinical medicine, 2026
  4. Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset. Pharmacoepidemiology and drug safety, 2025
  5. Global Rise of Compounded Weight-Loss Medicines: A Worrisome Trend. Journal of the Endocrine Society, 2025
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Compounded Weight Loss Medications in context

Australia compared

  • Obesity (adults): 30.6% of adults (2024). World: 16.2% of adults (2024). 2nd highest of the 15 countries we cover in APAC.[1]
  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[2]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[3]

Questions, answered with public data

How much research is published on Compounded Weight Loss Medications?
PubMed lists 9 papers added since January 2021 that match this market, worldwide.[4]
What does WHO report for Australia?
Obesity (adults): 30.6 % of adults in 2024, the latest WHO figure.[1]
How many people in Australia are 65 or older?
18.1% of people were 65 or older in 2025.[5]

[1] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[4] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

[5] World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 13 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Compounded Weight Loss Medications in Australia? Our analysts can size it for your plan. Talk to us See the public data Obesity (adults) for every country, free. Open the Public Health Dashboard

From our blog

Weight Management Supplements in the GLP-1 Era2.6 billion adults are overweight. GLP-1 medicines are changing weight care, while most supplements lack… Snoring and Sleep Apnoea Devices: Sleeping BetterAn estimated 936 million adults have obstructive sleep apnoea, and most are undiagnosed. CPAP machines, oral… Diabetes Medicines: How Treatment Choices Are ChangingWHO counts 830 million people with diabetes, and 59% of adults with diabetes took no medicine for it in 2022…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Australia

See all
Same topic, other categories

Related on obesity and pharmacy and generics

See the topic